The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to reports of the medication being subpotent.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has initiated a nationwide recall of the thyroid medication levothyroxine sodium. According to coverage from News4JAX, the recall affects multiple dosage strengths of the drug across the United States.
Reports from WTHR characterize the medication as a 'subpotent drug.' Outlets including WSB-TV, NBC 7 San Diego, and EatingWell are highlighting the alert to inform consumers about the affected tablets. Future coverage is expected to detail specific instructions for affected patients and further clarify which dosage strengths are included in the recall.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 21m ago.
Quick answers
Which medication is being recalled?
The FDA has recalled levothyroxine sodium tablets.
Why is the medication being recalled?
The thyroid medication has been described as a 'subpotent drug'.
What is the scope of the recall?
The recall is nationwide and affects multiple dosage strengths across the U.S.
Coverage (6)
- Thyroid medication described as 'subpotent drug' recalled by FDA WKYC · 5h ago
- Recall alert: Thyroid medication Levothyroxine recalled nationwide WSB-TV · 5h ago
- Thyroid drug recall affects multiple dosage strengths across U.S. News4JAX · 5h ago
- FDA recalls levothyroxine sodium tablets. Here's what to know NBC 7 San Diego · 5h ago
- Thyroid medication described as 'subpotent drug' recalled by FDA WTHR · 5h ago
- The FDA Issued a Recall on Thyroid Medication Nationwide EatingWell · 5h ago
Topics
Related trends
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
Compounded GLP-1 drugs creating concern among doctors and FDA
Medical professionals and the FDA are raising alarms over the safety and legality of compounded GLP-1 weight-loss injections.
Cyclospora outbreak has many changing eating habits, CBS News poll finds; mixed and partisan confidence in FDA
A Cyclospora outbreak is shifting consumer eating habits and driving a surge in demand for local produce and home-growing solutions.
Transcript: Former FDA commissioner Dr. Scott Gottlieb on "Face the Nation with Margaret Brennan," July 26, 2026
Former FDA commissioner Dr. Scott Gottlieb warns that a Cyclospora outbreak is not yet under control and may stem from broad contamination in Central Mexico.
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly has shifted the FDA application timeline for its next-generation obesity drug, retatrutide, to the first quarter of 2027.